Cargando…

Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review

PURPOSE: To obtain an up-to-date overview of the measurement of patient experience of switching biologic treatment in patients with inflammatory arthritis (IA) or ulcerative colitis (UC). Secondary objectives included summarizing the types of patient-reported outcomes (PROs) used (if any), and relat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luttropp, Karin, Dalén, Johan, Svedbom, Axel, Dozier, Mary, Black, Christopher M, Puenpatom, Amy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034967/ https://www.ncbi.nlm.nih.gov/pubmed/32109997 http://dx.doi.org/10.2147/PPA.S238843

Ejemplares similares

Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study
por: Dalén, Johan, et al.
Publicado: (2020)

Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study
por: Dalén, Johan, et al.
Publicado: (2021)

Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review
por: Luttropp, Karin, et al.
Publicado: (2019)

Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication
por: Dalén, Johan, et al.
Publicado: (2023)

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
por: Svedbom, Axel, et al.
Publicado: (2017)

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
por: Svedbom, Axel, et al.
Publicado: (2017)

Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
por: Singh, Harpreet, et al.
Publicado: (2023)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Real-life evaluation of histologic scores for Ulcerative Colitis in remission
por: Arkteg, Christian Børde, et al.
Publicado: (2021)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States
por: Puenpatom, Amy, et al.
Publicado: (2017)

Biological therapy for ulcerative colitis
por: Arora, Zubin, et al.
Publicado: (2015)

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure
por: Bressler, Brian, et al.
Publicado: (2018)

Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
por: Lucaciu, Laura A., et al.
Publicado: (2021)

Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2021)

Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data
por: Black, Christopher M., et al.
Publicado: (2016)

Current and Emerging Biologics for Ulcerative Colitis
por: Park, Sung Chul, et al.
Publicado: (2015)

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
por: Huss, Viking, et al.
Publicado: (2023)

Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
por: Han, Minkyung, et al.
Publicado: (2020)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
por: Zingone, Fabiana, et al.
Publicado: (2020)

Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data
por: Constantin, Joelle, et al.
Publicado: (2019)

Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
por: Ye, Byong Duk, et al.
Publicado: (2021)

Significance of diagnosis and prognosis for appendiceal orifice inflammation in ulcerative colitis: a real-world study
por: Deng, Peng, et al.
Publicado: (2022)

Real-world effectiveness of ustekinumab for patients with ulcerative colitis: a systematic review and meta-analysis
por: Uchida, Genta, et al.
Publicado: (2023)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Real-World Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients: A Retrospective Cohort Study
por: State, Monica, et al.
Publicado: (2023)

Arthritis Associated with Ulcerative Colitis: Our Experience in Palermo
por: Geraci, A, et al.
Publicado: (2009)

Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis
por: Wang, Wenfei, et al.
Publicado: (2019)

Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis
por: Arivarasan, K, et al.
Publicado: (2016)

Real-world retention rates of biologics in patients with rheumatoid arthritis
por: Takami, Kenji, et al.
Publicado: (2023)

Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings
por: Okayasu, Motohiro, et al.
Publicado: (2019)

Remote Monitoring of Patient-Reported Outcomes in Ulcerative Colitis: A Prospective Real-World Pilot Study
por: Sebastian, Shaji, et al.
Publicado: (2019)

Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford
por: Pulusu, Samba Siva Reddy, et al.
Publicado: (2020)

Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
por: Long, Millie D, et al.
Publicado: (2020)

Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis
por: Chun, Jaeyoung
Publicado: (2021)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
por: Huang, Kaituo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3b491901j406iaamrpopk13nga